Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies
- PMID: 38916481
- DOI: 10.1080/14656566.2024.2373350
Evaluating bexicaserin for the treatment of developmental epileptic encephalopathies
Abstract
Introduction: Developmental epileptic encephalopathies (DEEs) pose significant challenges due to their refractory nature and limited treatment options. Despite advancements in genetic understanding, effective therapies targeting underlying pathophysiology are lacking. Serotoninergic dysfunction has been implicated in epilepsy, sparking interest in serotonin as a therapeutic target.
Area covered: This article explores the potential of bexicaserin, a selective 5-HT2C receptor agonist, as an adjunctive antiseizure medication in DEEs. Bexicaserin is thought to modulate GABAergic neurotransmission, suppressing central hyperexcitability. Preclinical studies demonstrate its efficacy across various seizure models. Clinical trials, including the Pacific Study, reveal promising results in reducing motor seizures. However, challenges such as adverse effects and treatment discontinuation underscore the need for further investigation.
Expert opinion: The efficacy of 5-HT2C serotoninergic agonists, validated in preclinical and clinical studies, highlights serotonin's role in DEEs. Bexicaserin offers new therapeutic possibilities, potentially synergizing with existing antiseizure medications. Polypharmacotherapy, targeting distinct pathways, may enhance therapeutic outcomes. Monitoring pharmacological interactions and addressing central nervous system comorbidities are crucial for optimizing treatment strategies. Further research is needed to elucidate bexicaserin's mechanisms and potential antiepileptogenic effects.
Keywords: 5-HT2C; Bexicaserin (LP352); antiseizure medication (ASM); developmental and epileptic encephalopathies (DEE); drug-resistant epilepsy (DRE); serotonin.
Similar articles
-
An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies.Int J Mol Sci. 2021 Aug 5;22(16):8416. doi: 10.3390/ijms22168416. Int J Mol Sci. 2021. PMID: 34445144 Free PMC article. Review.
-
Epilepsy surgery in developmental and epileptic encephalopathies.Epilepsy Behav. 2024 Oct;159:109985. doi: 10.1016/j.yebeh.2024.109985. Epub 2024 Aug 24. Epilepsy Behav. 2024. PMID: 39181112 Review.
-
Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies.Ther Adv Neurol Disord. 2023 Aug 30;16:17562864231191000. doi: 10.1177/17562864231191000. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37655228 Free PMC article. Review.
-
Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials.Ther Adv Rare Dis. 2024 Jun 22;18:26330040241249762. doi: 10.1177/26330040241249762. eCollection 2024 Jan-Dec. Ther Adv Rare Dis. 2024. PMID: 38911512 Free PMC article. Review.
-
What are the considerations when initiating treatment for epilepsy in children?Expert Rev Neurother. 2023 Jul-Dec;23(12):1081-1096. doi: 10.1080/14737175.2023.2288107. Epub 2023 Dec 15. Expert Rev Neurother. 2023. PMID: 38032395 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
